TY - JOUR T1 - Side Effects of COVID-19 Vaccines and Perceptions about COVID-19 and Its Vaccines in Bangladesh JF - medRxiv DO - 10.1101/2022.01.31.22270172 SP - 2022.01.31.22270172 AU - Md Mohsin AU - Sultan Mahmud AU - Ashraf Uddin Mian AU - Prottay Hasan AU - Abdul Muyeed AU - Md. Taif Ali AU - Fee Faysal Ahmed AU - Ariful Islam AU - Maisha Maliha Rahman AU - Mahfuza Islam AU - Md Hasinur Rahaman Khan AU - M. Shafiqur Rahman Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/03/07/2022.01.31.22270172.abstract N2 - Introduction One of the primary reasons for hesitancy in taking COVID-19 vaccines is the fear of side effects. This study primarily aims to inspect the potential side effects of the COVID-19 vaccines circulated in Bangladesh.Methods The study was a cross-sectional anonymous online survey conducted across Bangladesh. Data were collected from December 2 to December 26, 2021. The study included consenting (informed) Bangladeshi individuals aged 12 and above who had received at least one dose of the COVID-19 vaccines. Analyses were carried out through exploratory analysis, Chi-square test, and logistic regression.Results A total of 1,180 (males-63.89%, age 50 years or over-65.4%, rural-52.86%) vaccinated people participated in the study. Less than half of the participants (39.48%) reported at least one side effect after receiving their COVID-19 vaccine. Injection-site pain, fever, headache, redness/swelling at the injection site, and lethargy were the most commonly reported adverse effects, all of which were mild and lasted 1-3 days. Side effects were most prevalent (about 80%) among individuals who received Pfizer-BioNTech and Moderna vaccines and were least common among those who received Sinopharm and Sinovac vaccines (21%-28%). When compared to the Sinopharm vaccines, the OxfordAstraZeneca, Pfizer-BioNTech, and Moderna vaccines were 4.51 (95% CI: 2.53-8.04) times, 5.37 (95% CI: 2.57-11.22) times, and 4.28 (95% CI: 2.28-8.05) times likelier to produce side effects. Furthermore, males, those over 50 years old, urban dwellers, smokers, and those with underlying health issues had a considerably increased risk of developing side effects. A lack of confidence in vaccines’ efficacy and a substantial level of hesitancy in allowing children (age five years or over) and older people (70 years or over) to receive COVID-19 vaccines were also observed.Conclusion Side effects of COVID-19 vaccines are minimal, demonstrating their safety. Further studies are required to establish the efficacy of the vaccines.What is already known?Significant COVID-19 vaccine hesitancy has been observed globally, mainly due to vaccine safety and efficacy concerns. Until now, most of the data on COVID-19 vaccine safety and efficacy have been published in manufacturer-funded trials that adhere to regulatory criteria and are monitored by third parties. A lack of independent studies on vaccine safety may have a detrimental effect on vaccine acceptance, which should be intensified to combat the deadly virus.What are the new findings?After receiving the COVID-19 vaccines, less than half of the subjects experienced at least one side effect. The side effects were mild and regular and lasted 1-3 days only. Side effects were most prevalent among individuals who received Pfizer-BioNTech and Moderna vaccines and were least common among those who received Sinopharm and Sinovac vaccines. A lack of confidence in vaccines’ efficacy and a substantial level of hesitancy in allowing children (age five years or over) and older people (70 years or over) to receive COVID-19 vaccines were also observed.What do the new findings imply?Side effects of COVID-19 vaccines are minimal and regular, demonstrating their safety. Efforts should be made to disseminate such findings among marginalized people worldwide who showed greater vaccine hesitancy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study leads with explicit declarations of anonymity by design, objectives, and voluntary nature. Participants could skip any questions if they found one uncomfortable to answer. The study was approved by the Ethical Review Committee, Faculty of Biological Science and Technology, Jashore University of Science and Technology, Jashore-7408, Bangladesh (Ref: ERC/FBST/JUST/2022-97).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://osf.io/h6qwa/?view_only=e888b489ae3845ffb23014757f8528cd https://osf.io/h6qwa/?view_only=e888b489ae3845ffb23014757f8528cd ER -